Calls for Action and Leadership Concerns

There is a pressing need for intervention and oversight. Questions have been raised about the effectiveness of reporting mechanisms for such behaviour, including whether SCS can be held accountable or removed under the Debt Collectors Act. Furthermore, there are doubts regarding the leadership at SCS—specifically, whether Martie Snyman, the Managing Director, is exercising adequate control over the company. The prevalence of similar complaints and the absence of responses to negative reviews suggest a broader issue within the organisation. In summary, the conduct of SCS and Lancet Laboratories has caused significant distress, and there is an urgent demand for action to address these persistent problems.